144 related articles for article (PubMed ID: 20680285)
1. Theory-based analysis of anti-inflammatory effect of infliximab on Crohn's disease and rheumatoid arthritis.
Kimura K; Takayanagi R; Yokoyama H; Yamada Y
Rheumatol Int; 2012 Jan; 32(1):145-50. PubMed ID: 20680285
[TBL] [Abstract][Full Text] [Related]
2. Theory-based analysis of the anti-inflammatory effect of TNF inhibitors on rheumatoid arthritis.
Kimura K; Takayanagi R; Yokoyama H; Yamada Y
Drug Metab Pharmacokinet; 2014; 29(3):272-7. PubMed ID: 24418824
[TBL] [Abstract][Full Text] [Related]
3. Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease.
Furuya Y; Ozeki T; Takayanagi R; Yokoyama H; Okuyama K; Yamada Y
Drug Metab Pharmacokinet; 2007 Feb; 22(1):20-5. PubMed ID: 17329907
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
5. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling.
Kimura K; Yoshida A; Katagiri F; Takayanagi R; Yamada Y
Biopharm Drug Dispos; 2019 Jul; 40(7):250-261. PubMed ID: 31256430
[TBL] [Abstract][Full Text] [Related]
6. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.
Curtis JR; Kramer JM; Martin C; Saag KG; Patkar N; Shatin D; Burgess M; Xie A; Braun MM
Rheumatology (Oxford); 2007 Nov; 46(11):1688-93. PubMed ID: 17938138
[TBL] [Abstract][Full Text] [Related]
7. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
8. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
9. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
[TBL] [Abstract][Full Text] [Related]
10. Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients.
Finckh A; Dudler J; Wermelinger F; Ciurea A; Kyburz D; Gabay C; Bas S;
Joint Bone Spine; 2010 Jul; 77(4):313-8. PubMed ID: 20471890
[TBL] [Abstract][Full Text] [Related]
11. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and use of infliximab.
Klotz U; Teml A; Schwab M
Clin Pharmacokinet; 2007; 46(8):645-60. PubMed ID: 17655372
[TBL] [Abstract][Full Text] [Related]
14. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
15. Experience with anti-TNF-α therapy for orofacial granulomatosis.
Elliott T; Campbell H; Escudier M; Poate T; Nunes C; Lomer M; Mentzer A; Patel P; Shirlaw P; Brostoff J; Challacombe S; Sanderson J
J Oral Pathol Med; 2011 Jan; 40(1):14-9. PubMed ID: 21249727
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study.
Miheller P; Lakatos PL; Horváth G; Molnár T; Szamosi T; Czeglédi Z; Salamon A; Czimmer J; Rumi G; Palatka K; Papp M; Jakab Z; Szabó A; Gelley A; Lakatos L; Barta Z; Balázs C; Rácz I; Zeher M; Döbrönte Z; Altorjay I; Hunyady B; Simon L; Papp J; Banai J; Nagy F; Lonovics J; Ujszászy L; Muzes G; Herszényi L; Tulassay Z
BMC Gastroenterol; 2009 Sep; 9():66. PubMed ID: 19740450
[TBL] [Abstract][Full Text] [Related]
17. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.
van der Bijl AE; Breedveld FC; Antoni CE; Kalden JR; Kary S; Burmester GR; Beckmann C; Unnebrink K; Kupper H
Clin Rheumatol; 2008 Aug; 27(8):1021-8. PubMed ID: 18350329
[TBL] [Abstract][Full Text] [Related]
18. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease.
Kimura K; Yoshida A; Takayanagi R; Yamada Y
Biopharm Drug Dispos; 2018 Jun; 39(6):283-288. PubMed ID: 29790586
[TBL] [Abstract][Full Text] [Related]
20. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]